Clinical trials
Small Cell Carcinoma clinical trials
Below are recruiting small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 795 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04602377RecruitingPhase 2
Pembrolizumab with standard chemo for ovarian small cell cancer
This Phase 2 trial tests whether adding pembrolizumab (an immune medicine) to standard chemotherapy can improve outcomes for people with small cell cancer of the ovary that has not been treated before. It may help your immune system recognize and attack the cancer while you receive chemotherapy.
AngersAges 12 years+ - NCT07369596Recruiting
Chemotherapy doses and survival in older lung cancer patients
This study looks at how lowering chemotherapy doses affects survival in older patients with advanced lung cancer who do not have certain genetic mutations. It may help doctors understand the best way to treat this group.
Hong KongAges 65 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT05703516Recruiting
Study of Tabrecta for NSCLC with exon 14 skipping
This study follows people in South Korea who have a specific lung cancer genetic change called “exon 14 skipping” and are going to take Tabrecta (capmatinib). It helps collect real-world safety and results for using this medicine under routine care.
Daegu, Dalseo guAges 18–100 - NCT05955105RecruitingPhase 1/Phase 2
ILB-2109 plus toripalimab for advanced solid cancers
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
Jinan, ShandongAges 18–80 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This trial tests a new PET scanner that may help doctors see where cancer is in your body more clearly. It is for adults with lung, prostate, or head and neck cancer who are already scheduled for a PET-CT scan at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+ - NCT07266363Recruiting
Blood test for early detection of esophageal cancer
This study is testing a blood test to detect esophageal squamous cell cancer early. Researchers are looking for a pattern of molecules in the blood that could signal the presence of this cancer.
Monrovia, CaliforniaAges 18 years+ - NCT06899789Recruiting
Long-term follow-up of colitis from checkpoint inhibitors
This study follows people who developed colitis (inflammation in the colon) after receiving immune checkpoint inhibitors for cancer. Researchers want to learn about long-term effects and outcomes.
Pavia, PaviaAges 18 years+ - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT07407933RecruitingPhase 1/Phase 2
YL201 with other cancer drugs for advanced solid tumors
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT07689643RecruitingEarly Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Wuhan, HubeiAges 18 years+ - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT06336187Recruiting
Active monitoring for small kidney tumors
This study tests whether closely monitoring small kidney tumors (less than 4 cm) with regular imaging is a safe and effective option for people who cannot or choose not to have immediate treatment. It involves a biopsy at the start to confirm the tumor type.
NovaraAges 18 years+ - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06980272RecruitingPhase 3
A new drug for advanced lung cancer that hasn't been treated yet
This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.
ShanghaiAges 18 years+ - NCT07510724Recruiting
Real-world study of Tislelizumab for lung cancer
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell carcinoma?
- Yes. Clin2 currently lists 795 recruiting small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.